Relative Enhanced Diffusivity (RED) expresses the relative change in ADC between lower and higher b-value regimes. The purpose of this study was to investigate the diagnostic potential and repeatability of RED as a biomarker for prostate cancer (PCa).
Ten (10) healthy volunteers and 28 high-risk patients diagnosed with PCa underwent diffusion-weighted MRI. For the healthy volunteers, the repeatability of RED was good to acceptable. For the patients, RED was able to discriminate tumors from healthy tissue in the peripheral zone using either b=50 or b=400 mm/s2 as the intermediate b-value (p < 0.001).